Patents by Inventor Philippe L. Durette

Philippe L. Durette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5629322
    Abstract: Disclosed herein are compounds of Formula I ##STR1## and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 13, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Ravindra N. Guthikonda, Stephan K. Grant, Malcolm Maccoss, Shrenik K. Shah, Kothandaraman Shankaran, Charles G. Caldwell, Philippe L. Durette
  • Patent number: 5591737
    Abstract: New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R.sub.4 is (a) ##STR2## or (b) ##STR3## where R.sub.x is carboxy C.sub.1-6 alkyl, benzyloxycarbonylC.sub.1-3 alkyl, or t-butoxycarbonylC.sub.1-3 alkyl,whereinQ is a covalent bond or ##STR4## wherein R.sub.5 and R.sub.6 are each individually C.sub.1-3 alkyl or hydrogen,Y is ##STR5## or a covalent bond.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: January 7, 1997
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Conrad P. Dorn, Philippe L. Durette, Paul E. Finke, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Soumya P. Sahoo, Jeffrey J. Hale, Thomas J. Lanza, William K. Hagmann
  • Patent number: 5359071
    Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable salt or ester thereof, wherein R.sup.1 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;R.sup.2 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;R.sup.3 is selected from the group consisting of C.sub.1-10 alkoxyl, C.sub.1-10 alkyl and cyano;R.sup.4 is selected from the group consisting of C.sub.1-10 alkenyloxyl, C.sub.1-10 alkoxyl, C.sub.1-10 alkyl, C.sub.1-10 alkylcarbamic, C.sub.1-10 alkylcarbonyloxyl, carbonyl, hydroxyl, and --NHR.sup.5, andR.sup.5 is selected from the group consisting of hydrogen and C.sub.1-10 alkylcarbonyl. Such compounds are useful as selective antagonists of testosterone 5.alpha.-reductase 1.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: October 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Craig K. Esser, William Hagmann, Ihor E. Kopka
  • Patent number: 5236899
    Abstract: Cyclosporin analogs containing a MeAla or MeAbu residue at the 6-position of the cyclic undecapeptide have been discovered to sensitize multidrug resistant cells to certain chemotherapeutic agents. These cyclosporin analogs have also been shown to increase the sensitivity of cells already susceptible to the chemotherapeutic agents. In addition, these cyclosporin A analogs lack the nephrotoxic and immunosuppressive activity of cyclosporin A.
    Type: Grant
    Filed: August 23, 1991
    Date of Patent: August 17, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 5227467
    Abstract: New immunosuppressive cyclosporin analogs are disclosed having one or more fluorinated amino acids. These analogs may also have a "C-9 amino acid" wherein the double bond is replaced by a heteroatom such as sulfur or oxygen.
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: July 13, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Arsenio A. Pessolano, Janos Kollonitsch
  • Patent number: 5104862
    Abstract: New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described.
    Type: Grant
    Filed: March 20, 1991
    Date of Patent: April 14, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Malcolm Maccoss
  • Patent number: 5100880
    Abstract: New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described.
    Type: Grant
    Filed: March 20, 1991
    Date of Patent: March 31, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Malcolm Maccoss
  • Patent number: 5068248
    Abstract: Method for increasing resistance to gastro-intestinal irritation, and for the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandin and/or leukotriene mediated diseases comprising the administration to a subject in need of such treatment, a non-toxic therapeutically effective amount of compound of formula I: ##STR1##
    Type: Grant
    Filed: June 22, 1989
    Date of Patent: November 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Allan N. Tischler, Philippe L. Durette, Bruce E. Witzel, Kathleen M. Rupprecht, Timothy F. Gallagher, Marvin M. Goldenberg, Debra L. Allison
  • Patent number: 5019568
    Abstract: Disclosed are pharmaceutical compositions for enhancing human host resistance against opportunistic infection in an individual immunocompromised by an AIDS-related virus, consisting essentially of an anti-viral, anti-AIDS drug selected from the group consisting of ansamycin, ribavirin, dideoxycitidine, HPA-23, AL-721, foscarnet, and azidothymidine and a glycolipid compound consisting essentially of the formula: ##STR1## where: R.sup.1 is .alpha. or .beta.-D-1-thiomannopyranoside, .alpha. or .beta.-L-1-thiofucopyranoside.
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, William K. Hagmann, Mitree M. Ponpipom
  • Patent number: 5006532
    Abstract: 3-Hydroxyazabenzo[b]thiophene derivatives having optionally 2-aryl, 2-aralkyl, 2-alkyl or 2-alkenyl substituents were prepared by, among other methods, ring closure of an appropriately substituted benzylthio-alkoxycarbonyl-pyridine. These compounds are found to be useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases such as psoriasis and atopic eczema, cardiovascular disorders, inflammatory diseases and other leukotriene mediated diseases.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: April 9, 1991
    Assignee: Merck & Co. Inc., Inc.
    Inventors: Robert K. Baker, Arsenio A. Pessolano, Kathleen M. Rupprecht, Philippe L. Durette
  • Patent number: 4970199
    Abstract: Disclosed are steroidal derivatives of glycolipids, in which steroids are bridged, via a medium length hydrocarbon chain, to 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses in combination with an anti-AIDS drug, that protect an immunocomprimised hot, particularly resulting from an AIDS-related virus, against opportunistic infection.
    Type: Grant
    Filed: July 10, 1989
    Date of Patent: November 13, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, William K. Hagmann, Mitree M. Ponpipom
  • Patent number: 4942154
    Abstract: Disclosed are steroidal derivatives of glycolipids, in which steroids are bridged, via a medium length hydrocarbon chain, to 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses that protect an immunocompromised host, particularly resulting from an AIDS-related virus, against opportunistic infection.
    Type: Grant
    Filed: June 18, 1987
    Date of Patent: July 17, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Mitree M. Ponpipom, William K. Hagmann
  • Patent number: 4925831
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDs-related (HIV) virus.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: May 15, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4923852
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDS-related (HIV) virus.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: May 8, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4914188
    Abstract: Novel cyclosporin analogs containing a MeAla or MeAbu residue at the 6-position of the cyclic undecapeptide have been synthesized and found unexpectedly to exhibit antagonistic activity toward cyclosporin A binding to its cytosolic protein receptor, cyclophilin, without being immunosuppressive.
    Type: Grant
    Filed: November 16, 1987
    Date of Patent: April 3, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Francis J. Dumont, Philippe L. Durette, Arsenio A. Pessolano, Joshua S. Boger, Nolan H. Sigal
  • Patent number: 4904672
    Abstract: 3-Hydroxyazabenzo[b]thiophene derivatives having optionally 2-aryl, 2-aralkyl, 2-alkyl or 2-alkenyl substituents were prepared by, among other methods, ring closure of an appropriately substituted benzylthioalkoxycarbonyl-pyridine. These compounds are found to be useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases such as psoriasis and atopic eczema, cardiovascular disorders, inflammatory disease and other leukotriene mediated diseases.
    Type: Grant
    Filed: April 28, 1988
    Date of Patent: February 27, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Kathleen M. Rupprecht, Arsenio A. Pessolano, Philippe L. Durette
  • Patent number: 4894392
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance host resistance to infectious organisms. Such agents are administered prophylactically to individuals whose resistance to infection is comprised by chemotherapy, surgery, burns or other forms of severe stress.
    Type: Grant
    Filed: May 12, 1988
    Date of Patent: January 16, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Timothy F. Gallagher
  • Patent number: 4868155
    Abstract: Disclosed are specific dipeptidyl 4-0, 6-0-acyl-2-amino-2-deoxy-D-glucose derivatives which, either alone, or in combination with an anti-AIDS drug, e.g. azidothymidine, protect against opportunistic bacterial, fungal and viral infection in a human host immunocompromised by an AIDS-related virus, as well as help to suppress the AIDS-related virus itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 19, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Conrad P. Dorn
  • Patent number: 4868157
    Abstract: Disclosed are specific dipeptidyl 2-amino-1,2-dideoxy-D-glucoses which, either alone, or in combintion with an anti-AIDS drug, e.g. azidothymidine, protect an immunocompromised human host, resulting from an AIDS-related virus, against opportunistic, bacterial, fungal and viral infections, as well as help to suppress the AIDS-related virus itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 19, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4866035
    Abstract: Disclosed are specific dipeptidyl saccharide derivatives which alone, or in combination with an anti-AIDS drug, e.g. azidothymidine, provide protection against opportunistic infection in human individuals whose resistance to infection has been specifically suppressed by an AIDS-related (HIV) virus, as well as help to suppress the AIDS-related infection itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 12, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette